Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT-03: Sacituzumab Govitecan vs Treatment of Physician's Choice in 1L Metastatic Triple-Negative Breast Cancer
NCT05382299Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Jul 2022
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 30
01
Overview
A Phase 3 trial of sacituzumab govitecan in triple-negative breast cancer (TNBC), sponsored by Gilead Sciences. Started Jul 2022; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05382299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382299.